TMO — Thermo Fisher Scientific Inc. (NYSE: TMO) — Analysis Report

Report date: 2026-09-18 | Sector: Health Care | Industry: Life Sciences Tools & Services

1. Critical Data-Availability Notice (read first)

Before the analysis, I must flag a deployment constraint that materially shapes what follows:

• get_stock_data → returned NO_DATA_AVAILABLE (external market data tools disabled in this deployment). No OHLCV CSV was retrieved.
• get_verified_market_snapshot → returned NO_DATA_AVAILABLE. Per instructions, the verified snapshot is the source of truth for any exact price, OHLCV, or indicator-value claim — no such verified data exists for this report. I therefore make no price-level claims, no support/resistance claims, and no historical-validation claims anywhere below.
• get_indicators → returned NO_DATA_AVAILABLE. Indicator values (RSI, MACD, SMAs, ATR, VWMA) could not be computed because the input CSV was unavailable.

Consequence: the only quantitative market-state evidence permitted in this analysis is the QuantOrb money-flow engine snapshot in the source documents (as of the 2026-09-17 US session). All chart-technique content below is a selection and playbook framework — the indicators I would run and why — not a claim about their current readings. Anything not covered by the source documents is stated as "not available in provided documents."

2. Indicator Selection (up to 8, chosen for complementarity)

Given the documented regime — a volume-weighted momentum signal (MFI 67.35) labeled CONTINUATION with moderate strength (0.6449) — the correct toolkit is one that (a) validates that the trend is real, (b) times entries within it, (c) cross-checks volume-weighted momentum against price-only momentum, and (d) sizes risk to volatility.

Deliberate exclusions (redundancy control): - macdh — derived entirely from macd/macds; keeping all three triples-counts the same information. - boll, boll_ub, boll_lb — Bollinger volatility/overbought logic overlaps with both RSI (momentum extremes) and ATR (volatility); three band lines would add little independent signal.

3. What the Source Documents Establish

3.1 Quantitative regime — QuantOrb money-flow engine (as of 2026-09-17 US session)

• MFI reading: 67.35 — an elevated, constructive reading. Under common MFI conventions the overbought zone begins near 80; 67.35 sits in the upper-middle range — bullish momentum without an extreme reading. Note: the engine's own thresholds are not defined in the documents, so this is contextual framing, not the engine's rule.
• Signal: CONTINUATION, strength 0.6449 — the engine classifies the current condition as a likely persistence of the existing move, with moderate conviction. Presuming a 0–1 bounded strength scale, 0.6449 sits in the upper-middle; the scale itself is not defined in the provided documents.
• The document explicitly states this is a quantitative screen output, not a recommendation, and the snapshot is a site bake of the 05:30 HKT run covering the 2026-09-17 US session.

Nuance: A CONTINUATION label at sub-extreme MFI is the textbook profile for buying strength early in a leg, not chasing an exhausted one — but with no verified price data, this remains a regime read, not an entry.

3.2 Fundamentals — 8-K Item 2.02 press release, 2026-07-23 (Q2 2026, quarter ended June 27, 2026)

• Revenue $11.99B, +10%, of which +5% organic (headline arithmetic implication: roughly half of reported growth came from non-organic sources — acquisitions/FX — my inference from the headline, not a disclosed split).
• GAAP diluted EPS $4.68, +9%; Adjusted EPS $6.03, +13%. Adjusted outgrew GAAP by 4 pts — the 10-K MD&A references its non-GAAP reconciliation section, but the Q2 reconciliation items themselves are not available in provided documents.
• Management tone: CEO Marc Casper — end markets "continue to strengthen," "continued share gain," "well positioned to deliver a great 2026." No numeric guidance appears in the excerpt. The document is explicitly not an earnings call transcript, so there is no Q&A color, and guidance figures are not available in provided documents.
• Product catalyst: next-generation Orbitrap platforms with AI-driven analytics launched at the ASMS conference — a concrete innovation datapoint supporting the growth narrative.

Fit with the quant signal: A fundamentals picture of strengthening end markets and share gains is directionally consistent with a money-flow CONTINUATION regime — fundamental confirmation, at an 8-week remove.

3.3 Macro and risk — 10-K (filed 2026-02-26)

• Growth is explicitly tied to served-market growth; cyclical downturns are called out for certain businesses.
• Significant inflationary pressures in 2025, with U.S. and international inflation "continu[ing] at elevated levels" — cost/margin risk that post-dates nothing in the 8-K excerpt.
• Sensitivity to global economy and to European and U.S. conditions specifically.

Fit with the quant signal: The principal thesis risk is macro-cyclical, not company-specific execution. A CONTINUATION signal in a cyclical-tools franchise is inherently more fragile than one in a defensive business.

3.4 Institutional positioning — 13F-HR snapshot as of 2026-03-31 (5 tracked filer rows; non-exhaustive; up-to-45-day statutory lag, and now ~5.5 months stale)

• Derived by simple summation of these five rows (my arithmetic, not a disclosed figure): combined holdings ~10.55M shares, net QoQ change ~+289,592 shares (~+2.8%). Three adders vs. two reducers.
• Largest absolute add: 1832 Asset Management (+725,093); largest absolute trim: Pictet (−400,813).
• Caveats that matter: five filers is a tiny, non-exhaustive sample; positions are 5.5 months old; this is a periodic regulatory disclosure, not real-time portfolio data. Treat as weak directional anecdote only.

4. Synthesis and Actionable Framework (process, not price calls)

Regime read: The evidence stack — elevated-but-not-extreme volume-weighted momentum (MFI 67.35), a moderate-conviction CONTINUATION label, Q2 revenue/EPS acceleration with strengthening end markets, and a modestly net-positive (if stale and tiny-sample) institutional add — paints a constructive, mid-trend picture with identifiable macro risk. Nothing in the documents indicates exhaustion; nothing in the documents justifies chasing without confirmation, because no verified price data exists in this deployment.

Actionable checklist to execute once live data is available (each step uses a selected indicator): 1. Trend gate (close_50_sma, close_200_sma): Act on the CONTINUATION signal only if price trades above both averages and the 50 SMA sits above the 200 SMA. If the averages disagree, downgrade the signal to watch-list. 2. Timing trigger (close_10_ema): Use 10 EMA behavior for entry refinement; the MFI snapshot is one session old and a fast average is the appropriate bridge to "now." 3. Momentum confirmation (macd/macds): Require the MACD line above its signal line (or a fresh bullish cross) before entry; treat any MACD bearish divergence against rising MFI as a veto. 4. Cross-momentum check (rsi): RSI should corroborate, not contradict, MFI 67.35 — ideally constructive without sitting in the extreme zone. RSI-vs-MFI divergence is the single best early-reversal tell in this toolkit. 5. Volume validation (vwma): Price holding above a rising VWMA confirms the flow behind MFI; price below a flattening VWMA suggests the flow is fading. 6. Risk definition (atr): Define stops and position size as ATR multiples, never as fabricated fixed price levels — the only defensible method when verified price levels are unavailable. 7. Thesis monitors: Q3 2026 results (first report after the strong Q2 print; date not available in provided documents), inflation trajectory per the 10-K risk language, and the next 13F cycle for whether the adder/reducer mix persists.

5. Explicit "Not Available in Provided Documents" List

Current/verified price and OHLCV • all computed indicator values • Bollinger/ATR levels • valuation metrics • Q2 non-GAAP reconciliation items • numeric FY2026 guidance • segment/geographic revenue detail • balance-sheet and cash-flow detail • earnings-call commentary • next earnings date • real-time institutional positioning • the QuantOrb strength-scale definition. Additionally, the verified market snapshot tool returned NO_DATA_AVAILABLE and could not serve as source of truth — this is a tool-availability discrepancy, not a data conflict, but it means every price-dependent claim above is deliberately withheld.

6. Key Points Summary Table

Bottom line: The permitted evidence describes a constructive continuation regime for TMO — elevated volume-weighted momentum aligned with accelerating Q2 2026 fundamentals — tempered by cyclical/inflation risk and only weak, stale institutional confirmation. With the verified-snapshot tool unavailable, no entry levels can responsibly be stated; the 8-indicator checklist above is the disciplined path to convert this regime read into a trade once live data is restored.

Overall Sentiment: Mildly Bullish (Score: 6.2/10) Confidence: Low

TMO sentiment report, 2026-09-11 to 2026-09-18

Source-by-source breakdown

1. News (Yahoo Finance, past 7 days): No news feed data was available in this deployment — the placeholder stated external market data tools are disabled. News sentiment for the window is not available in provided documents.

2. StockTwits (retail social, past 7 days): Feed unavailable in this deployment. Retail bullish/bearish ratio not available in provided documents.

3. Reddit (r/wallstreetbets, r/stocks, r/investing, past 7 days): Feed unavailable in this deployment. Community sentiment is silent — not available in provided documents.

4. QuantOrb money-flow engine (2026-09-17 US session): MFI reading of 67.35 with a CONTINUATION signal (strength 0.6449). MFI in the 60–70 zone suggests net buying pressure without being at overbought extremes (>80 would flag over-extension risk). A continuation signal implies the existing trend is quantitatively favored to persist. Note: this is a screen output, not a recommendation.

5. Q2 2026 8-K press release (2026-07-23): Fundamentals are a strongly positive backdrop — revenue +10% to $11.99B (5% organic), GAAP diluted EPS +9% to $4.68, adjusted EPS +13% to $6.03. Management flagged "customer activity across our end markets continued to strengthen" and continued share gain, plus new next-generation Orbitrap platforms with AI-driven analytics. These are pre-existing catalysts supporting a mildly bullish lean even though the release predates the analysis window.

6. 13F-HR snapshot (positions as of 2026-03-31, lagged): Mixed institutional positioning across 5 tracked filers — 3 added (1832 Asset Management +58.3%, Unisphere +5.1%, GMO +3.7%) and 2 trimmed (Pictet -16.3%, Flossbach von Storch -10.3%). Net direction mildly positive but from a small, stale sample.

7. 10-K risk factors (filed 2026-02-26): Standard cyclicality/inflation risk language; 2025 inflationary pressures noted as continuing at elevated levels. Mildly cautionary but boilerplate.

Cross-source divergences and alignments

With all three real-time sentiment feeds unavailable, no cross-source divergence can be measured for the 7-day window. The available sources (money flow, fundamentals, lagged institutional positioning) align mildly bullish.

Dominant narrative themes

• Strengthening end-market demand and share gain (8-K).
• Quantitative money-flow continuation (MFI 67.35).
• Split institutional accumulation vs. trimming (13F).

Catalysts and risks surfaced by the data

• Catalysts: continuation of the momentum flagged by the money-flow engine; Q2's Orbitrap/AI product cycle; implied positive trajectory into full-year 2026 per management.
• Risks: MFI approaching overbought territory if buying intensifies; elevated inflation and cyclicality per 10-K; stale/limited institutional data; absence of any fresh news or retail flow means unidentified catalysts could exist in the window.

Summary table

Caveats: All three real-time sentiment sources returned placeholders; the resulting score reflects only quantitative money flow, fundamentals, and stale institutional data, so confidence is low. This is sentiment signal for the trader to weigh alongside fundamentals and technicals — not a price call or recommendation.

TMO (Thermo Fisher Scientific Inc., NYSE: TMO) — Weekly News & Macro Research Report

Analysis date: 2026-09-18 | Sector: Health Care | Industry: Life Sciences Tools & Services

1. Data Availability Notice (Tool Status)

All four external research tools were invoked for this workflow and are disabled in this deployment:

Consequently, the following are not available in provided documents: company-specific news for the past week, global macroeconomic news, current FRED macro data (CPI, core PCE, unemployment, fed funds rate, 10-year Treasury, yield curve), prediction-market probabilities, TMO's current share price, valuation multiples, trading volume, Q3 2026 guidance, and the Q3 2026 earnings date. This report is built exclusively from the four permitted source documents, and every figure below is traceable to them.

2. Company-Specific Signal State — TMO

QuantOrb money-flow snapshot (2026-09-17 US session): - MFI reading: 67.35 — the Money Flow Index is a bounded 0–100 oscillator; a print in the upper half of the range (without reaching the conventional ~80 exhaustion zone) indicates net buying pressure / demand dominance in the most recent US session, without signaling an extreme. - Signal: CONTINUATION, strength 0.6449 — a moderate-to-solid conviction trend-continuation classification. The document itself explicitly cautions this is a quantitative screen output, not a recommendation. - The snapshot is one session old (baked from the 05:30 HKT run covering 2026-09-17). No prior-session readings are available in provided documents, so trend-of-the-signal cannot be established — not available in provided documents.

Interpretation for traders: The quantitative state is constructive — buying pressure is dominant and the engine classifies the move as continuation rather than exhaustion/reversal. But with no signal history and no price/volume data available, this single snapshot should be treated as a current-state check, not a standalone entry trigger.

3. Fundamentals — Most Recent Hard Data (Q2 2026, reported 2026-07-23)

The 8-K Item 2.02 press release (Exhibit 99.1) — note: a press release, NOT an earnings call transcript — for the quarter ended June 27, 2026:

Derived observations (arithmetic from disclosed figures): - Total growth (+10%) vs. organic (+5%) implies roughly 5 percentage points of revenue growth from non-organic drivers (acquisitions/divestitures/FX). The excerpt does not itemize the components — the split is an inference from the two disclosed growth rates. - Adjusted EPS ($6.03) exceeds GAAP EPS ($4.68) by $1.35/share of non-GAAP adjustments. The composition is not itemized in the excerpt; quality-of-earnings diligence on the reconciliation would be required — detail not available in provided documents. - Implied prior-year baselines (back-solved from growth rates): ~$4.29 GAAP EPS and ~$5.34 adjusted EPS in Q2 2025 — derived arithmetic, not separately disclosed figures.

Management commentary (as quoted in the release): - CEO Marc N. Casper: "Our end markets continue to strengthen… leading to continued share gain," and "At the halfway point of the year, we are well positioned to deliver a great 2026." - Product cycle: at the American Society for Mass Spectrometry conference, TMO introduced next-generation Orbitrap platforms with AI-driven analytics — a tangible innovation datapoint supporting the growth strategy. - Execution framework: PPI Business System credited for the quarter's performance.

Timing caveat: This is the most recent fundamental datapoint on file, and it is ~8 weeks old as of the analysis date. Anything about July–September demand trends, Q3 guidance, or the Q3 report date is not available in provided documents.

4. Institutional Positioning (13F-HR, as of 2026-03-31)

Tracked cohort of 5 filers in the quantorb filers dataset (a quarter-end snapshot subject to the statutory lag of up to 45 days — i.e., at least ~5.5 months stale as of today; a newer June 30 filing cycle exists by regulation but its contents are not available in provided documents):

Derived aggregate (arithmetic on disclosed rows): - Total tracked holdings: 10,547,237 shares. - Gross adds: 915,236 shares; gross trims: 625,644 shares → net +289,592 shares (~+2.7% of the tracked aggregate). Mixed but net-positive positioning in this small cohort: 3 adders vs. 2 trimmers. - Percent-change distortion warning: the largest percentage add (+58.3%, 1832 Asset Management) comes off the smallest base (~1.24M prior shares); in absolute shares the add (+725,093) is nonetheless the single largest position change in the cohort. The two trims are mid-sized percentage reductions from larger bases. - Scope caveats: this is the dataset's tracked top-holder snapshot, not an exhaustive list of 13F filers; it is a periodic regulatory disclosure, not real-time portfolio data.

5. Macro & World State

What the documents establish: - Inflation (as of 10-K filing, 2026-02-26): TMO's own 10-K risk factors state that "both domestic and international markets experienced significant inflationary pressures in 2025 and inflation rates in the U.S., as well as in other countries in which we operate, continue at elevated levels." This is the only macro datapoint in the permitted evidence — a company-filed characterization as of late February 2026, not a current reading. - Demand cyclicality: the same 10-K flags that served markets may "decline, do not grow as anticipated or experience cyclicality," and that certain businesses face "periodic, cyclical downturns." For a Life Sciences Tools & Services name, end-market funding cycles (pharma/biotech/academia/government demand) are a first-order risk per the company's own disclosure. - Counterpoint from the 8-K: despite the disclosed inflation backdrop, TMO grew adjusted EPS 13% in Q2 2026 with management citing strengthening end markets — evidence the company was absorbing the cost environment as of the June-quarter print.

What cannot be assessed (all not available in provided documents): current CPI/core PCE prints, unemployment, the fed funds rate, the 10-year Treasury yield, yield-curve shape, any weekly global macro or geopolitical developments, Fed meeting outcomes, and market-implied probabilities of a Fed rate cut or 2026 recession. No macro catalysts for the coming week can be identified from the permitted evidence.

6. Actionable Insights (evidence-tied, scenario-framed)

1. Quantitative lean is constructive. The 2026-09-17 money-flow state (MFI 67.35, CONTINUATION, strength 0.6449) is directionally consistent with the last hard fundamental print (Q2: double-digit revenue growth, 13% adjusted EPS growth, management citing strengthening end markets and share gains). If expressing a directional view in TMO, the permitted evidence tilts toward the long side — framed as a momentum-with-confirmation stance, sized with respect for the stale data, and explicitly not on the screen output alone.
2. Respect the information vacuum. The freshest fundamentals are 8 weeks old (July 23), the institutional data is ~5.5 months stale (March 31), and there is zero news flow, macro data, or price context available. Treat any position as operating on a lag; the highest-priority verification items are: (a) the Q3 2026 earnings release (date not available in provided documents), (b) fresh macro prints, and (c) the June 30 13F cycle.
3. Watch the organic/non-organic growth mix. The ~5-point gap between total (+10%) and organic (+5%) Q2 growth means part of the headline strength is M&A/FX-driven. If organic growth decelerates in Q3 while total growth holds, the quality of the growth story deteriorates even if headlines look fine.
4. Monitor the non-GAAP wedge. The $1.35/share gap between adjusted ($6.03) and GAAP ($4.68) EPS is material; if the wedge widens further in upcoming quarters without itemized justification, that is a quality-of-earnings yellow flag.
5. Defined risk triggers: (a) a money-flow signal flip from CONTINUATION, or an MFI reading that rolls over sharply from the 67 area; (b) any Q3 print showing organic growth materially below the 5% Q2 pace; (c) renewed confirmation of the 10-K's cyclical-downturn risk (a demand contraction in served markets). Any of these would argue for cutting exposure regardless of the current constructive signal.
6. Institutional signal is mildly supportive but low-weight. Net +2.7% accumulation across the tracked cohort (3 adds / 2 trims) leans positive, but with only 5 filer rows, a March 31 snapshot, and known percentage-base distortions, this is corroborating color at best — not a standalone input.

7. Key Points Summary Table

Bottom line: Within the strict evidence set, TMO presents a coherent constructive picture — a continuation-class money-flow signal as of the 2026-09-17 session, sitting on top of a strong Q2 2026 print (revenue +10%, adjusted EPS +13%, strengthening end markets) and net-positive institutional accumulation in the tracked cohort. The dominant trading consideration is not the evidence on hand but the evidence that is missing: no current macro data, no news flow, no price context, and fundamentals that are eight weeks old. Actionable stance: the permitted evidence supports a constructive, confirmation-dependent tilt in TMO, with position sizing held back until the Q3 2026 print, fresh macro readings, and updated institutional filings close the information gap.

Fundamental Research Report: Thermo Fisher Scientific Inc (TMO)

Analysis date: 2026-09-18 | Ticker: TMO (NYSE) | Sector: Health Care | Industry: Life Sciences Tools & Services

1. Tool Availability Notice (Important)

All four assigned data tools — get_fundamentals, get_balance_sheet, get_cashflow, and get_income_statement — were called for TMO and returned NO_DATA_AVAILABLE: external market data tools are disabled in this deployment. Accordingly, structured balance sheet, cash flow, and income statement extracts are not available in provided documents, and this report is built exclusively from the four permitted source documents: the QuantOrb money-flow snapshot, the SEC 10-K excerpt (filed 2026-02-26), the Q2 2026 earnings 8-K press release (2026-07-23), and the 13F-HR holdings snapshot (as of 2026-03-31).

2. Company Profile

• Name / Listing: Thermo Fisher Scientific Inc (TMO), NYSE — self-described in its Q2 2026 press release as "the world leader in serving science."
• Headquarters: Waltham, Massachusetts (press release dateline).
• Sector / Industry (QuantOrb classification): Health Care; Life Sciences Tools & Services.
• Leadership: Marc N. Casper is chairman and chief executive officer (quoted in the Q2 2026 release).
• Operational framework: Management attributes execution strength to the company's "PPI Business System" and its "proven growth strategy" (Q2 2026 8-K).
• Additional profile details (founding date, employee count, segment structure, full product catalog) — not available in provided documents.

3. Quantitative Money-Flow Snapshot (as of 2026-09-17 US session)

Per the QuantOrb money-flow engine (site bake of the 05:30 HKT orb run):

• MFI reading: 67.35 — a firmly positive reading indicating net buying pressure under the engine's framework (interpretation of absolute MFI thresholds is standard convention, not defined in the source document).
• Signal: CONTINUATION, with signal strength 0.6449 — a moderate-to-strong conviction reading pointing toward continuation of the prevailing trend rather than reversal.
• Critical caveat from the source itself: "The signal is a quantitative screen output, not a recommendation."

Trader takeaway: The short-term flow backdrop for TMO as of the 2026-09-17 session is constructive, with no signal of distribution/reversal from this engine.

4. Latest Reported Financials — Q2 2026 (8-K Item 2.02, filed 2026-07-23)

Quarter ended June 27, 2026:

Derived figures (arithmetic implied by the stated growth rates; not directly stated in the document): - Implied Q2 2025 revenue: ≈ $10.90 billion (11.99 ÷ 1.10) - Implied Q2 2025 GAAP diluted EPS: ≈ $4.29; implied adjusted EPS: ≈ $5.34 - GAAP-to-adjusted EPS gap: $1.35 (adjusted is ~28.8% above GAAP), reflecting non-GAAP exclusions that the 10-K says are reconciled in the "Non-GAAP Measures" section of MD&A. - The 10% headline growth vs. 5% organic implies roughly 5 points of growth from non-organic sources (acquisitions/currency), though the exact breakdown is not available in provided documents.

Qualitative highlights from the release: - CEO Marc N. Casper: "Our end markets continue to strengthen… leading to continued share gain," and "At the halfway point of the year, we are well positioned to deliver a great 2026." - Headline framing: "Customer Activity Across Our End Markets Continued to Strengthen." - Capital deployment / product pipeline: The company advanced its growth strategy by "launching a range of high-impact, innovative new products," including next-generation Orbitrap platforms with AI-driven analytics introduced at the American Society for Mass Spectrometry conference. - Full-year 2026 guidance specifics, margin detail, segment revenue breakdown, buybacks, dividends, and cash flow figures — not available in provided documents (the excerpt is truncated after the Growth Strategy section).

5. Annual Filing Insights — 10-K (filed 2026-02-26, FY context 2025)

The available excerpt is limited to the Business risk-factor opening and the MD&A opening, but it yields the following:

Key disclosed risks: 1. Served-market dependency: "Our growth depends in part on the growth of the markets which we serve. Any decline or lower than expected growth in our served markets would diminish demand for our products and services, which would adversely affect our financial statements." 2. Cyclicality: "Certain of our businesses operate in industries that may experience periodic, cyclical downturns." 3. Macro sensitivity: The business "is affected by general economic conditions, both inside and outside the U.S." 4. Inflation: "Both domestic and international markets experienced significant inflationary pressures in 2025 and inflation rates in the U.S., as well as in other countries in which we operate, continue at elevated levels" — with specific reference to economic conditions in Europe and the U.S.

MD&A / reporting conventions: - MD&A for 2023 is incorporated by reference to the company's 2024 Form 10-K. - The company explicitly uses non-GAAP measures, reconciled in the "Non-GAAP Measures" section of MD&A (consistent with the adjusted EPS figure in the Q2 8-K). - Reported amounts are calculated on underlying unrounded amounts.

Trader takeaway: The 10-K flags macro/inflation and end-market cyclicality as the principal fundamental risk vectors — relevant context because TMO's own Q2 narrative hinges on "end markets continuing to strengthen."

6. Institutional Ownership — 13F-HR Snapshot (as of 2026-03-31)

The QuantOrb filers dataset tracks 5 institutional filer rows for TMO (a partial top-holder snapshot, not exhaustive; subject to the statutory 45-day reporting lag — note this snapshot is now roughly two reporting cycles stale as of 2026-09-18):

Reading of the snapshot: - Three accumulators vs. two reducers. Gross buying (+915,236 shares) exceeded gross selling (−625,644 shares). - Standout accumulation: 1832 Asset Management L.P. raised its position +58.3% (+725,093 shares) — the largest single move in the dataset, though from a smaller base. - Largest reduction: Pictet Asset Management cut −16.3% (−400,813 shares), partially offset by GMO and Unisphere adds. - Caveats: This is a regulatory, quarter-end disclosure — not real-time portfolio data — and covers only 5 tracked filers, so it is not representative of total institutional ownership.

7. Financial History & Data Gaps

What the documents support: Q2 2026 results vs. implied Q2 2025 comparatives (Section 4); FY2025 macro/inflation commentary from the 10-K; institutional positioning as of 2026-03-31.

Explicitly not available in provided documents (and returned NO_DATA_AVAILABLE from tools): balance sheet items (cash, debt, equity, leverage), cash flow statement items (operating cash flow, capex, free cash flow, buybacks, dividends), full income statement detail (gross/operating margin, net income), FY2025 full-year results, Q1 2026 results, current price/valuation multiples, full-year 2026 guidance, and segment-level breakdowns. Traders should treat conclusions here as directionally informed rather than fully validated against balance-sheet fundamentals.

8. Actionable Insights for Traders (TMO)

1. Momentum/flow context is supportive: MFI of 67.35 with a CONTINUATION signal (strength 0.6449) as of 2026-09-17 suggests the recent trend had net-buying participation — a constructive backdrop for trend-following entries, per the engine's screen (not a recommendation).
2. Earnings trajectory is accelerating: Q2 2026 delivered double-digit revenue growth (+10%) with adjusted EPS growth (+13%) outpacing GAAP EPS growth (+9%) — and management characterized end markets as strengthening with continued share gains. This is the strongest fundamental data point in the document set.
3. Organic vs. total growth gap warrants monitoring: 5% organic vs. 10% total implies roughly half of growth came from non-organic sources; traders seeking purely organic momentum should verify the acquisition/FX split in the full release (breakdown not available in provided documents).
4. Non-GAAP reliance is material: Adjusted EPS ($6.03) runs ~28.8% above GAAP EPS ($4.68); those anchoring valuation to adjusted figures should reconcile against the GAAP base per the 10-K's non-GAAP conventions.
5. Macro/inflation is the disclosed swing factor: The 10-K explicitly ties growth to served-market expansion and flags elevated inflation persisting beyond 2025 — a risk to the "end markets strengthening" thesis if macro conditions in Europe or the U.S. deteriorate.
6. Institutional tape is net positive but stale and partial: +2.8% net accumulation across 5 tracked filers (led by 1832 Asset Management's +58.3% add) supports a constructive ownership narrative, but the 2026-03-31 snapshot is roughly two quarters old and non-exhaustive — weight it lightly.
7. Key gap to close before sizing positions: No balance sheet, cash flow, or margin data is available in this document set; traders should seek those statements independently before underwriting the thesis.

9. Key Points Summary Table

Bottom line: The documented fundamental picture for TMO is constructive — accelerating Q2 2026 results ($11.99B revenue, +10%; adjusted EPS $6.03, +13%), strengthening end markets per management, net institutional accumulation, and a positive money-flow CONTINUATION signal as of 2026-09-17. The principal caveats are (a) roughly half of revenue growth was non-organic, (b) a wide GAAP/non-GAAP EPS gap, (c) disclosed inflation/cyclicality risks, and (d) the complete absence of balance-sheet, cash-flow, and valuation data in the provided documents — which should be sourced separately before any position is sized.